‘First Of Many’ For Kabi As It Rolls Out Its First Biosimilar – Pegfilgrastim
German Firm Awaits 1 April Q-Code; Planned Launch Of Adalimumab In July
Fresenius Kabi has delivered on long held ambitions to join the biosimilars party in the US, offering another pegfilgrastim subcutaneous injectable in a crowded market of biosimilar sponsors.
